---
title: "Talon Capital - Unit | 10-Q: FY2026 Q2 Revenue: USD 0"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/265987059.md"
published_at: "2025-11-14T21:41:00.000Z"
---

# Talon Capital - Unit | 10-Q: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD 0.03.

EBIT: As of FY2026 Q2, the actual value is USD -776.13 K.

### Segment Revenue

-   **Interest Income**: For the three months ended September 30, 2025, interest income on cash held in the trust account was $617,036. For the period from May 1, 2025 (inception) through September 30, 2025, the interest income was also $617,036.

### Operational Metrics

-   **Net Income**: For the three months ended September 30, 2025, net income was $383,939. For the period from May 1, 2025 (inception) through September 30, 2025, net income was $346,682.
-   **Operating Costs**: For the three months ended September 30, 2025, operating costs were $159,097. For the period from May 1, 2025 (inception) through September 30, 2025, operating costs were $196,354.
-   **Compensation Expense**: For both the three months ended September 30, 2025, and the period from May 1, 2025 (inception) through September 30, 2025, compensation expense was $74,000.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the period from May 1, 2025 (inception) through September 30, 2025, net cash used in operating activities was - $263,849.
-   **Net Cash Used in Investing Activities**: For the period from May 1, 2025 (inception) through September 30, 2025, net cash used in investing activities was - $249,000,000.
-   **Net Cash Provided by Financing Activities**: For the period from May 1, 2025 (inception) through September 30, 2025, net cash provided by financing activities was $252,360,484.

### Future Outlook and Strategy

-   **Core Business Focus**: Talon Capital Corp. intends to effectuate a business combination using cash derived from the proceeds of the initial public offering and the sale of private placement units. The company has 24 months from the closing date of the Initial Public Offering to complete its initial Business Combination.
-   **Non-Core Business**: The company has not selected any specific Business Combination target but intends to focus on target businesses in the energy and power industries.

### Related Stocks

- [TLNCU.US - Talon Capital - Unit](https://longbridge.com/en/quote/TLNCU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 辛巴威修憲草案 擬延長總統姆南加瓦任期至 2030 年 | 辛巴威內閣通過憲法修正草案，計劃將總統姆南加瓦的任期延長至 2030 年。該草案將總統任期從 5 年延長至 7 年，並由國會選出總統，需經國會審議。姆南加瓦的執政黨 ZANU-PF 去年已通過相關計劃，旨在讓其在 2028 年任期屆滿後繼續 | [Link](https://longbridge.com/en/news/275518658.md) |
| HYPE 在一週內下跌 18%：是否會再次測試 27 美元的支撐水平？ | HYPE，Hyperliquid DEX 的原生幣，已從其年高點 38 美元下跌 18%，目前交易價格低於 30 美元。看跌趨勢受到空頭頭寸上升和混合衍生品數據的支持。多空比為 0.91，表明更多交易者預計價格將進一步下跌。如果 HYPE  | [Link](https://longbridge.com/en/news/275467898.md) |
| GLP-1 類藥物可能會導致患者出現壞血病 | GLP-1 減肥藥物，包括 Ozempic 和 Wegovy，與壞血病病例相關，這是一種由維生素 C 缺乏引起的罕見疾病。紐卡斯爾健康科學學院的 Clare Collins 的研究強調了使用這些藥物的患者可能面臨的營養不良風險。壞血病的症狀 | [Link](https://longbridge.com/en/news/275772745.md) |
| 隨着阿里拉姆製藥競相擴大 AMVUTTRA 的全球運營規模以實現 2030 年的增長目標，執行風險正在逼近 | 阿里拉姆製藥（ALNY）在尋求全球擴張和實現 2030 年增長目標時面臨重大執行風險，特別是在 ATTR-CM 領域 AMVUTTRA 的商業化方面。員工人數和地理覆蓋範圍的快速增加正在給現有基礎設施帶來壓力，這可能導致運營和監管能力的延遲 | [Link](https://longbridge.com/en/news/275858709.md) |
| 收入超預期：Engineers India Limited 的收入超出分析師預期 27% | 印度工程有限公司（NSE:ENGINERSIN）報告的收入為 120 億印度盧比，超出分析師預期 27%。儘管股價上漲 18% 至 202 印度盧比，分析師卻將 2027 年的每股收益預測下調至 8.15 印度盧比，下降幅度達到 41%。預 | [Link](https://longbridge.com/en/news/275992842.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.